The FDA is taking action against non-FDA-approved GLP-1 drugs, aiming to curb the mass-marketing of compounded versions. This move is designed to protect consumers by ensuring the safety, efficacy, and quality of these medications. The agency is particularly concerned about products being marketed as alternatives to approved drugs, especially by compounding pharmacies like Hims & Hers.

The FDA's actions are a response to concerns about the quality and potential risks associated with these compounded alternatives. The agency is also addressing misleading advertising that falsely claims these non-approved drugs are equivalent to their FDA-approved counterparts. This includes claims about generic versions and clinical proof of results, which are not substantiated.

The FDA will leverage all available enforcement tools to address these violations, potentially including legal action. This crackdown follows warning letters issued in the fall of 2025. Entities involved in manufacturing, distributing, or marketing unapproved compounded GLP-1 products should be aware of potential legal consequences.

Fact: The FDA's authority to regulate drugs stems from the Federal Food, Drug, and Cosmetic Act of 1938, which granted the agency the power to ensure drug safety and efficacy before they are marketed.

Ultimately, this is a move to protect consumers from potentially unsafe compounded medications that are being marketed under false pretenses.